In stark contrast to most newly approved drugs, Eli Lilly’s Zepbound for chronic weight management needs little introduction.
Thousands of media stories and social media posts heralded the news of Zepbound’s FDA approval in November and then again with its availability in pharmacies earlier this month. Add that to broader conversations on social media in recent years about GLP-1s and weight loss, including off-label use of type 2 diabetes treatment Mounjaro, which is the same molecule as Zepbound, and it’s not surprising that the launch is in full swing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
